Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Vaccines

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 148 articles:
HTML format
Text format



Single Articles


    February 2017
  1. JANES HE, Cohen KW, Frahm N, De Rosa SC, et al
    Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  2. SKOWRONSKI DM, Chambers C, De Serres G, Sabaiduc S, et al
    Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada, 2010-11 to 2014-15.
    J Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    



  3. Flu vaccine - too much of a good thing?
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  4. PETRIE JG, Monto AS
    Untangling the Effects of Prior Vaccination on Subsequent Influenza Vaccine Effectiveness.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  5. MARTINEZ-BAZ I, Casado I, Navascues A, Diaz-Gonzalez J, et al
    Effect of Repeated Vaccination With the Same Vaccine Component Against Influenza A(H1N1)pdm09.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  6. UPRETY P, Lindsey JC, Levin MJ, Rainwater-Lovett K, et al
    Inflammation and Immune Activation in Antiretroviral-Treated HIV-1-Infected African Infants and Rotavirus Vaccine Responses.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  7. LINDESMITH LC, Mallory ML, Jones TA, Richardson C, et al
    Impact of Pre-Exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.
    J Infect Dis. 2017 Feb 1. doi: 10.1093.
    PubMed     Text format    


    January 2017
  8. COHEN JI
    Vaccination to Reduce Reactivation of Herpes Simplex Virus 2.
    J Infect Dis. 2017 Jan 11. pii: jix006. doi: 10.1093.
    PubMed     Text format    


  9. DO VA, Biering-Sorensen S, Fisker AB, Bale C, et al
    Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.
    J Infect Dis. 2017 Jan 10. pii: jiw512. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. RESIK S, Tejeda A, Diaz M, Okayasu H, et al
    Boosting Immune Responses Following Fractional-Dose Inactivated Poliovirus Vaccine: A Randomized, Controlled Trial.
    J Infect Dis. 2017 Jan 9. pii: jiw492. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. NYOMBAYIRE J, Anzala O, Gazzard B, Karita E, et al
    First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    J Infect Dis. 2017;215:95-104.
    PubMed     Text format     Abstract available


  12. WEI M, Meng F, Wang S, Li J, et al
    2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study.
    J Infect Dis. 2017;215:56-63.
    PubMed     Text format     Abstract available


  13. PIERCE KK, Whitehead SS, Kirkpatrick BD, Grier PL, et al
    A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Delta30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.
    J Infect Dis. 2017;215:52-55.
    PubMed     Text format     Abstract available


    December 2016
  14. HADLER JL
    Christmas-New Year influenza lull: not too late for vaccination.
    J Infect Dis. 2016 Dec 28. pii: jiw643. doi: 10.1093.
    PubMed     Text format    


  15. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A Virus Endemic Circulation in Israel Despite Universal Toddler Vaccination Since 1999 and Low Clinical Incidence in All Age Groups.
    J Infect Dis. 2016 Dec 24. doi: 10.1093.
    PubMed     Text format    


  16. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups.
    J Infect Dis. 2016 Dec 23. pii: jiw611. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. CHENG A, Chang SY, Sun HY, Tsai MS, et al
    Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy.
    J Infect Dis. 2016 Dec 23. pii: jiw605. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. DONKEN R, Schurink-van 't Klooster TM, Schepp RM, van der Klis FR, et al
    Immune responses after two- versus three-doses of HPV vaccination up to 4(1/2) years post vaccination: an observational study among Dutch routinely vaccinated girls (HPV2D).
    J Infect Dis. 2016 Dec 23. pii: jiw588. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. MOSLEY YC, Radder JE, Berndt A, HogenEsch H, et al
    Genome-Wide Association Mapping of the Antibody Response to Diphtheria-Tetanus-acellular Pertussis Vaccine in Mice.
    J Infect Dis. 2016 Dec 23. pii: jiw587. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. HEARD I, Tondeur L, Arowas L, Demazoin M, et al
    Effectiveness of HPV vaccination on prevalence of vaccine genotypes in young sexually active women in France.
    J Infect Dis. 2016 Dec 23. pii: jiw639. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. TRIEU MC, Zhou F, Lartey S, Jul-Larsen A, et al
    Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination.
    J Infect Dis. 2016 Dec 22. pii: jiw619. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. JOHN J, Giri S, Karthikeyan AS, Lata D, et al
    The duration of intestinal immunity after an inactivated poliovirus vaccine booster dose in children immunized with oral vaccine: a randomised controlled trial.
    J Infect Dis. 2016 Dec 21. pii: jiw595. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. PETRIE JG, Parkhouse K, Ohmit SE, Malosh RE, et al
    Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains.
    J Infect Dis. 2016;214:1947-1951.
    PubMed     Text format     Abstract available


  24. RAMSAUER K, Tangy F
    Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
    J Infect Dis. 2016;214.
    PubMed     Text format     Abstract available


  25. DEZURE AD, Berkowitz NM, Graham BS, Ledgerwood JE, et al
    Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
    J Infect Dis. 2016;214.
    PubMed     Text format     Abstract available


  26. ERASMUS JH, Rossi SL, Weaver SC
    Development of Vaccines for Chikungunya Fever.
    J Infect Dis. 2016;214.
    PubMed     Text format     Abstract available


  27. HENEIN S, Swanstrom J, Byers AM, Moser JM, et al
    Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue exposed individuals.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  28. FEDSON DS
    Statins, Influenza Vaccination and Influenza.
    J Infect Dis. 2016.
    PubMed     Text format    


  29. COLLETT MS, Hincks JR, Benschop K, Duizer E, et al
    Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  30. FEDSON DS
    Statins, Influenza Vaccination and Influenza.
    J Infect Dis. 2016 Dec 7. doi: 10.1093.
    PubMed     Text format    


    November 2016
  31. BERENSON AB, Laz TH, Rahman M
    Reduction in vaccine-type human papillomavirus prevalence among adult females in the United States, 2009-2012.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  32. ABEID KA, Jani B, Cortese MM, Kamugisha C, et al
    Monovalent Rotavirus Vaccine Effectiveness and Impact on Rotavirus Hospitalizations in Zanzibar, Tanzania: Data from the First 3 Years Post-Introduction.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  33. MACHALEK DA, Chow EP, Garland SM, Wigan R, et al
    Human papillomavirus prevalence in unvaccinated heterosexual males following a national female vaccination program.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    October 2016
  34. WU Y, Chakravarty S, Li M, Wai TT, et al
    Development of a live attenuated bivalent oral vaccine against Shigella sonnei shigellosis and typhoid fever.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  35. HARRIS VC, Armah G, Fuentes S, Korpela KE, et al
    The infant gut microbiome correlates significantly with rotavirus vaccine response in rural Ghana.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  36. ITURRIZA-GOMARA M, Cunliffe NA
    Could the gut microbiome be key to understanding and improving rotavirus vaccine performance in high disease burden settings?
    J Infect Dis. 2016.
    PubMed     Text format    


  37. SCHLECHT NF, Diaz A, Shankar V, Szporn AH, et al
    RISK OF DELAYED HPV VACCINATION IN INNER-CITY ADOLESCENT WOMEN.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  38. MORI I
    Vaccination Effectively Prevents Central Nervous System Invasion by Influenza A(H5N1) Virus Through the Olfactory Pathway: A Proposed Mechanism of Neuroprotection.
    J Infect Dis. 2016.
    PubMed     Text format    


  39. LELIC A, Verschoor CP, Lau VW, Parsons R, et al
    Immunogenicity of Varicella Zoster Vaccine and Immunologic Predictors of Response in a Cohort of Elderly Nursing Home Residents.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  40. JEYANATHAN M, Damjanovic D, Yao Y, Bramson J, et al
    Induction of an immune protective T cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in man.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  41. XIONG X, Jiao J, Gregory AE, Wang P, et al
    Identification of Coxiella burnetii CD8+ epitopes and delivery by attenuated Listeria monocytogenes as a vaccine vector in a C57BL/6 mouse model.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available



  42. Live attenuated influenza vaccine in children induces B-cell responses in tonsils.
    J Infect Dis. 2016.
    PubMed     Text format    


    September 2016
  43. ENGLUND JA, Chu HY
    Vaccines Against Respiratory Syncytial Virus: The Time Has Come.
    J Infect Dis. 2016.
    PubMed     Text format    


  44. LANGLEY JM, Aggarwal N, Toma A, Halperin SA, et al
    A randomized, controlled, observer-blind Phase I study of the safety and immunogenicity of a Respiratory Syncytial Virus vaccine with or without alum adjuvant.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  45. HALSTEAD SB
    Dengue Vaccine Efficacy: Not a Zero Sum Game.
    J Infect Dis. 2016.
    PubMed     Text format    


  46. LIAO G, Li R, Li C, Sun M, et al
    Phase III Trial of a Sabin Strain-based Inactivated Poliovirus Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  47. GOO L, Dowd KA, Lin TY, Mascola JR, et al
    A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all Chikungunya virus genotypes.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  48. MADAN A, Segall N, Ferguson M, Frenette L, et al
    Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  49. SINGH DK, Dwivedi VP, Ranganathan A, Bishai WR, et al
    Blockade of the Kv1.3 K+ channel enhances BCG vaccine efficacy by expanding central memory T lymphocytes.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  50. REBER AJ, Kim JH, Coleman LA, Spencer SM, et al
    Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity with Past and Future Strains.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  51. EDWARDS KM, Keitel WA
    Challenges Remain for Influenza Vaccination of Children.
    J Infect Dis. 2016.
    PubMed     Text format    


  52. KIM JH, Mishina M, Chung JR, Cole KS, et al
    Cell-mediated immunity against antigenically drifted influenza A(H3N2) viruses in children during a vaccine mismatch season.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  53. SIEGERS JY, van den Brand JM, Leijten LM, van de Bildt MM, et al
    Vaccination Is More Effective Than Prophylactic Oseltamivir in Preventing CNS Invasion by H5N1 Virus via the Olfactory Nerve.
    J Infect Dis. 2016;214:516-24.
    PubMed     Text format     Abstract available


  54. ADLER SP, Manganello AM, Lee R, McVoy MA, et al
    A Phase 1 Study of Four Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in CMV Seronegative Men.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  55. PINTO LA, Kemp TJ, Torres BN, Isaacs K, et al
    THE QUADRIVALENT HPV VACCINE INDUCES HPV-SPECIFIC ANTIBODIES AT THE ORAL CAVITY: RESULTS FROM THE MID-ADULT MALE VACCINE TRIAL-THE MAM TRIAL.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  56. WILDER-SMITH A, Vannice KS, Hombach J, Farrar J, et al
    Population perspectives and WHO recommendations for CYD-TDV dengue vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


  57. HALSTEAD S
    Critique of WHO Approval of a Dengue Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


  58. WU S, Kroeker A, Wong G, He S, et al
    An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available



  59. A Randomized, Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in Rural Ghanaian Infants.
    J Infect Dis. 2016.
    PubMed     Text format    


    July 2016
  60. MCLEAN HQ, Chow BD, VanWormer JJ, King JP, et al
    The Effect of Statin Use on Influenza Vaccine Effectiveness.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  61. SHAFER WM
    Does the cervicovaginal microbiome facilitate transmission of Neisseria gonorrhoeae from women to men? Implications for understanding transmission of gonorrhea and advancing vaccine development.
    J Infect Dis. 2016.
    PubMed     Text format    


  62. JOHNSON RF, Kurup D, Hagen KR, Fisher C, et al
    An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  63. HOFT DF, Lottenbach K, Goll JB, Hill H, et al
    Priming Vaccination with H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  64. OLIVERA-BOTELLO G, Coudeville L, Fanouillere K, Guy B, et al
    Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue infections in healthy children and adolescents aged 2-16 years in Asia and Latin America.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    June 2016

  65. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.
    J Infect Dis. 2016.
    PubMed     Text format    


  66. ATMAR RL, Baehner F, Cramer JP, Song E, et al
    Rapid Responses to Two Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  67. JEGASKANDA S, Luke C, Hickman HD, Sangster MY, et al
    The generation and protective ability of influenza-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection or experimental challenge.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  68. MATTHIJSSE SM, Hontelez JA, Naber SK, Rozemeijer K, et al
    Public health benefits of routine human papillomavirus vaccination for adults in the Netherlands: a mathematical modeling study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  69. RAMPLING T, Ewer KJ, Bowyer G, Bliss CM, et al
    Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  70. BOWEN MD, Mijatovic-Rustempasic S, Esona MD, Teel EN, et al
    Rotavirus Strain Trends during the Post-Licensure Vaccine Era: United States, 2008-2013.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  71. REGULES JA, Cicatelli SB, Bennett JW, Paolino KM, et al
    Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria infection and immunogenicity study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  72. MEITES E, Gorbach PM, Gratzer B, Panicker G, et al
    Monitoring for HPV Vaccine Impact among Gay, Bisexual and other Men who have Sex with Men - United States, 2012-2014.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  73. TOTA JE, Ramanakumar AV, Villa LL, Richardson H, et al
    Cervical Infection with Vaccine Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  74. MOHN KG, Brokstad KA, Pathirana RD, Bredholt G, et al
    Live attenuated influenza vaccination in children induces B-cell responses in tonsils.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  75. SCRIBA TJ, Kaufmann SH, Lambert PH, Sanicas M, et al
    Vaccination against tuberculosis with whole cell mycobacterial vaccines.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  76. DE ST MAURICE A, Schaffner W, Griffin MR, Halasa N, et al
    Persistent gender disparities in invasive pneumococcal diseases in the conjugate vaccine era.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  77. LAPRISE JF, Markowitz LE, Chesson HW, Drolet M, et al
    COMPARING 2- AND 3-DOSE 9-VALENT HPV VACCINE SCHEDULES IN THE U.S.: A COST-EFFECTIVENESS ANALYSIS.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  78. PRELOG M, Gorth P, Zwazl I, Kleines M, et al
    Universal mass vaccination against Rotavirus: indirect effects on Rotavirus infections in neonates and non-vaccinated small infants not eligible for vaccination.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  79. FLANNERY B, Zimmerman RK, Gubareva LV, Garten RJ, et al
    Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  80. ALI D, Banda R, Mohammed A, Adagadzu J, et al
    Strengthening Routine Immunization in Areas of Northern Nigeria at High Risk for Polio Transmission During 2012-2014.
    J Infect Dis. 2016;213 Suppl 3:S147-50.
    PubMed     Text format     Abstract available


  81. GALI E, Mkanda P, Banda R, Korir C, et al
    Revised Household-Based Microplanning in Polio Supplemental Immunization Activities in Kano State, Nigeria. 2013-2014.
    J Infect Dis. 2016;213 Suppl 3:S73-8.
    PubMed     Text format     Abstract available


  82. JOHNSON MULUH T, Hamisu AW, Craig K, Mkanda P, et al
    Contribution of Environmental Surveillance Toward Interruption of Poliovirus Transmission in Nigeria, 2012-2015.
    J Infect Dis. 2016;213 Suppl 3:S131-5.
    PubMed     Text format     Abstract available


  83. CRAIG KT, Verma H, Iliyasu Z, Mkanda P, et al
    Role of Serial Polio Seroprevalence Studies in Guiding Implementation of the Polio Eradication Initiative in Kano, Nigeria: 2011-2014.
    J Infect Dis. 2016;213 Suppl 3:S124-30.
    PubMed     Text format     Abstract available


  84. MUSA A, Mkanda P, Manneh F, Korir C, et al
    Youth Group Engagement in Noncompliant Communities During Supplemental Immunization Activities in Kaduna, Nigeria, in 2014.
    J Infect Dis. 2016;213 Suppl 3:S91-5.
    PubMed     Text format     Abstract available


    April 2016
  85. PIGNY F, Lassus A, Terrettaz J, Tranquart F, et al
    Intranasal vaccination with Salmonella-derived SseB associated to gas-filled microbubbles partially protects against gut infection in mice.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  86. NEUZIL KM
    The Art and Science of Delivering Influenza Vaccines.
    J Infect Dis. 2016.
    PubMed     Text format    


  87. PETRIE JG, Ohmit SE, Truscon R, Johnson E, et al
    Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  88. PRADOS-ROSALES R, Carreno LJ, Weinrick B, Batista-Gonzalez A, et al
    The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  89. SIMONS BC, Spradling PR, Bruden DJ, Zanis C, et al
    A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B cellular immunity despite loss of antibody against hepatitis B surface antigen.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    March 2016
  90. CRABTREE JN, He W, Guan W, Flage M, et al
    Autoimmune variant PTPN22 C1858T is associated with impaired responses to influenza virus vaccination.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  91. MUTHUMANI K, Block P, Flingai S, Muruganantham N, et al
    Rapid and long-term immunity elicited by DNA encoded antibody prophylaxis and DNA vaccination against Chikungunya virus.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  92. LEITMAN EM, Hurst J, Mori M, Kublin J, et al
    Lower Viral Loads and Slower CD4 Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  93. WANG H, LeBert V, Li M, Lerksuthirat T, et al
    Mannose Receptor Is Required for Optimal Induction of Vaccine-Induced T-Helper Type 17 Cells and Resistance to Blastomyces dermatitidis Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  94. MINHINNICK A, Harris S, Wilkie M, Peter J, et al
    Optimization of a Human Bacille Calmette-Guerin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity.
    J Infect Dis. 2016;213:824-30.
    PubMed     Text format     Abstract available


    February 2016
  95. CLARK CE, Fay MP, Chico ME, Sandoval CA, et al
    Maternal helminth infection is associated with higher infant IgA titers to orally administered vaccines.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  96. ROTHMAN AL, Ennis FA
    Dengue vaccine: the need, the challenges and progress.
    J Infect Dis. 2016.
    PubMed     Text format    


  97. DURBIN AP, Kirkpatrick BD, Pierce KK, Carmolli MP, et al
    A 12-month interval dosing study in adults indicates that a single dose of the NIAID tetravalent dengue vaccine induces a robust neutralizing antibody response.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  98. YASSIN GM, Amin MA, Attia AS
    Immunoinformatics identifies a lactoferrin binding protein A peptide as a promising vaccine with a global protective prospective against Moraxella catarrhalis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  99. CHESSON HW, Laprise JF, Brisson M, Markowitz LE, et al
    The Impact and Cost-Effectiveness of 3 doses of 9-Valent Human Papillomavirus (HPV) Vaccine among US Females Previously Vaccinated with 4-Valent HPV Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  100. KONTIO M, Palmu AA, Syrjanen RK, Lahdenkari M, et al
    Similar antibody levels in 3-year old children vaccinated against measles mumps and rubella at the age of 12 months or 18 months.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  101. ZURLI V, Gallotta M, Taccone M, Chiarot E, et al
    Positive contribution of adjuvanted influenza vaccines on the resolution of bacterial superinfections.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  102. PICHICHERO ME, Casey JR, Almudevar A, Basha S, et al
    Functional Immune Cell Differences Associated with Low Vaccine Responses in Infants.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  103. TSENG HF, Harpaz R, Luo Y, Hales CM, et al
    Declining effectiveness of herpes zoster vaccine in adults 60 years and older.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  104. MASCITELLI L, Goldstein MR
    How regulatory T cells induction by statin drugs may impair influenza vaccine immunogenicity and effectiveness.
    J Infect Dis. 2016.
    PubMed     Text format    


  105. PAYNE RO, Milne KH, Elias SC, Edwards NJ, et al
    Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  106. TITA AT, Andrews WW
    Influenza Vaccination and Antiviral Therapy in Pregnant Women.
    J Infect Dis. 2016.
    PubMed     Text format    


  107. PUTHANAKIT T, Huang LM, Chiu CH, Tang RB, et al
    A randomised open trial comparing 2-dose regimens of the HPV-16/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus 3 doses in women aged 15-25 years.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  108. WARIGON C, Mkanda P, Muhammed A, Estano A, et al
    Demand Creation for Polio Vaccine in Persistently Poor-Performing Communities of Northern Nigeria: 2013-2014.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  109. THORNE L, Arias A, Goodfellow I
    Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis.
    J Infect Dis. 2016;213 Suppl 1:S27-31.
    PubMed     Text format     Abstract available


    January 2016
  110. ZAMAN K, Fleming JA, Victor JC, Yunus M, et al
    Non-interference of rotavirus vaccine with measles-rubella vaccine at 9 months and improvements in anti-rotavirus immunity: a randomized trial.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  111. KLING HM, Norris KA
    Vaccine-induced Immunogenicity and Protection against Pneumocystis pneumonia in Non-human Primate Model of HIV-Pneumocystis Co-Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  112. CUNLIFFE N, Kang G
    Can changes to scheduling enhance the performance of rotavirus vaccines in low income countries?
    J Infect Dis. 2016.
    PubMed     Text format    


  113. ARMAH G, Lewis KD, Cortese MM, Parashar UD, et al
    A Randomized Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in Rural Ghanaian Infants.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  114. PENNINGTON SH, Thompson AL, Wright AK, Ferreira DM, et al
    Oral typhoid vaccination with Ty21a generates Ty21a-responsive and heterologous influenza-responsive CD4+ and CD8+ T-cells at the human intestinal mucosa.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  115. VAN DAMME P
    Long-term Protection After Hepatitis B Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


  116. BRUCE MG, Bruden D, Hurlburt D, Zanis C, et al
    Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  117. PIROTH L, Launay O, Michel ML, Bourredjem A, et al
    Vaccination against hepatitis B virus in HIV-1 infected patients with isolated anti-HBc: the ANRS HB EP03 CISOVAC prospective study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  118. KUNG F, Kaur S, Smith AA, Yang X, et al
    A Borrelia burgdorferi surface-exposed transmembrane protein lacking detectable immune responses supports pathogen persistence and constitutes a vaccine target.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  119. PAVIA AT
    Influenza Vaccine Effectiveness: Mysteries, Enigmas, and a Few Clues.
    J Infect Dis. 2016.
    PubMed     Text format    


  120. GAGLANI M, Pruszynski J, Murthy K, Clipper L, et al
    Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    December 2015
  121. WARIGON C, Mkanda P, Banda R, Zakari F, et al
    The Journalists Initiatives on Immunisation Against Polio and Improved Acceptance of the Polio Vaccine in Northern Nigeria 2007-2015.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  122. SIRIVICHAYAKUL C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, et al
    Safety and immunogenicity of a tetravalent dengue vaccine (TDV) in healthy children and adults in endemic regions: a randomized, placebo-controlled Phase 2 study.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  123. VAN DER MAAS NA, Woudenberg T, Hahne S, de Melker HE, et al
    Tolerability of early measles-mumps-rubella vaccination in infants aged 6-14 months during a measles outbreak in the Netherlands in 2013-2014.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  124. SCHILLER JT, Lowy DR
    Reply to Nalin.
    J Infect Dis. 2015;212:2021-2.
    PubMed     Text format    


  125. ABU RAYA B, Srugo I, Kessel A, Peterman M, et al
    The Decline of Pertussis-Specific Antibodies After Tetanus, Diphtheria, and Acellular Pertussis Immunization in Late Pregnancy.
    J Infect Dis. 2015;212:1869-73.
    PubMed     Text format     Abstract available


  126. SOBHANIE M, Matsuoka Y, Jegaskanda S, Fitzgerald T, et al
    Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9).
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  127. MACATANGAY BJ, Riddler SA, Wheeler ND, Spindler J, et al
    Therapeutic vaccination with dendritic cells loaded with autologous HIV-1-infected apoptotic cells.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  128. BAGGA B, Cehelsky JE, Vaishnaw A, Wilkinson T, et al
    Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults.
    J Infect Dis. 2015;212:1719-25.
    PubMed     Text format     Abstract available


    November 2015
  129. TOURAY K, Mkanda P, Tegegn SG, Nsubuga P, et al
    Tracking Vaccination Teams During Polio Campaigns in Northern Nigeria by Use of Geographic Information System Technology: 2013-2015.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  130. FIEBELKORN AP, Coleman LA, Belongia EA, Freeman SK, et al
    Measles virus neutralizing antibody response, cell-mediated immunity, and IgG antibody avidity before and after a third dose of measles-mumps-rubella vaccine in young adults.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  131. OHMIT SE, Petrie JG, Malosh RE, Johnson E, et al
    Substantial Influenza Vaccine Effectiveness Observed in Households with Children in a Season in which A (pH1N1) Predominated (2013-2014).
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  132. ARRIOLA CS, Chaves SS
    Reply to Chughtai et al.
    J Infect Dis. 2015;212:1684-5.
    PubMed     Text format    


  133. CHUGHTAI AA, Rahman B, MacIntyre CR
    Commentary On Arriola et al. Antivirals and Effect Modification in Influenza Studies.
    J Infect Dis. 2015;212:1683-4.
    PubMed     Text format    


  134. ARNEMO M, Watle SS, Schoultz KM, Vainio K, et al
    Stability of a Vesicular Stomatitis Virus-Vectored Ebola Vaccine.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  135. GILBERT PB, Gabriel EE, Hudgens MG, Miao X, et al
    Reply to Dunning.
    J Infect Dis. 2015;212:1521-3.
    PubMed     Text format    


    October 2015
  136. HARARI A, Chen Z, Rodriguez AC, Hildesheim A, et al
    Cross-protection of the bivalent human papillomavirus (HPV) vaccine against variants of genetically related high-risk HPV infections.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  137. BLACK S, Nicolay U, Del Giudice G, Rappuoli R, et al
    Influence of Statins on Influenza Vaccine Response in Elderly Individuals.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  138. OMER SB, Phadke VK, Bednarczyk RA, Chamberlain AT, et al
    Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  139. ATMAR RL, Keitel WA
    Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here?
    J Infect Dis. 2015.
    PubMed     Text format    


  140. TCHAKOUTE CT, Hesseling AC, Blakney AK, Jaspan HB, et al
    Reply to Thysen et al.
    J Infect Dis. 2015;212:1342-3.
    PubMed     Text format    


  141. JONES T
    Comment on Ly and Klevens, Trends in Disease and Complications of Hepatitis A Virus Infection.
    J Infect Dis. 2015.
    PubMed     Text format    


  142. SMITHER SJ, Nelson M, Eastaugh L, Nunez A, et al
    Experimental Respiratory Infection of Marmosets (Callithrix jacchus) With Ebola Virus Kikwit.
    J Infect Dis. 2015;212 Suppl 2:S336-45.
    PubMed     Text format     Abstract available


  143. BAUSCH DG, Clougherty MM
    Ebola Virus: Sensationalism, Science, and Human Rights.
    J Infect Dis. 2015;212 Suppl 2:S79-83.
    PubMed     Text format     Abstract available


  144. GEISBERT TW, Strong JE, Feldmann H
    Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.
    J Infect Dis. 2015;212 Suppl 2:S91-7.
    PubMed     Text format     Abstract available


  145. BRANNAN JM, Froude JW, Prugar LI, Bakken RR, et al
    Interferon alpha/beta Receptor-Deficient Mice as a Model for Ebola Virus Disease.
    J Infect Dis. 2015;212 Suppl 2:S282-94.
    PubMed     Text format     Abstract available


    September 2015
  146. CLIFF JM, Cho JE, Lee JS, Ronacher K, et al
    Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    April 2015
  147. MONTO AS, Petrie JG, Cross RT, Johnson E, et al
    Antibody to the influenza neuraminidase: an independent correlate of protection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    March 2015
  148. NAJARRO K, Nguyen H, Chen G, Xu M, et al
    Telomere Length as an Indicator of the Robustness of B- and T-cell Response to Influenza in Older Adults.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: